{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T20:21:34Z","timestamp":1769113294073,"version":"3.49.0"},"reference-count":84,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2021,9,12]],"date-time":"2021-09-12T00:00:00Z","timestamp":1631404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Research, Development and Innovation Fund of Hungary","award":["NVKP_16-1\u20132016-0017"],"award-info":[{"award-number":["NVKP_16-1\u20132016-0017"]}]},{"name":"Ministry for Innovation and Technology in Hungary","award":["2020-4.1.1.-TKP2020"],"award-info":[{"award-number":["2020-4.1.1.-TKP2020"]}]},{"name":"National Research, Development and Innovation Office (NKFIH) of Hungary","award":["K134939"],"award-info":[{"award-number":["K134939"]}]},{"name":"New National Excellence Program of the Ministry of Human Capacities of Hungary","award":["\u00daNKP-21-3-II-SE-45"],"award-info":[{"award-number":["\u00daNKP-21-3-II-SE-45"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Selective sodium\u2013glucose cotransporter 2 (SGLT2) inhibitors reduced the risk of hospitalization for heart failure in patients with or without type 2 diabetes (T2DM) in large-scale clinical trials. The exact mechanism of action is currently unclear. The dual SGLT1\/2 inhibitor sotagliflozin not only reduced hospitalization for HF in patients with T2DM, but also lowered the risk of myocardial infarction and stroke, suggesting a possible additional benefit related to SGLT1 inhibition. In fact, several preclinical studies suggest that SGLT1 plays an important role in cardiac pathophysiological processes. In this review, our aim is to establish the clinical significance of myocardial SGLT1 inhibition through reviewing basic research studies in the context of SGLT2 inhibitor trials.<\/jats:p>","DOI":"10.3390\/ijms22189852","type":"journal-article","created":{"date-parts":[[2021,9,12]],"date-time":"2021-09-12T21:45:57Z","timestamp":1631483157000},"page":"9852","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Effects of SGLT2 Inhibitors beyond Glycemic Control\u2014Focus on Myocardial SGLT1"],"prefix":"10.3390","volume":"22","author":[{"given":"Alex","family":"Sayour","sequence":"first","affiliation":[{"name":"Heart and Vascular Center, Department of Cardiology, Semmelweis University, V\u00e1rosmajor str. 68, H-1122 Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mih\u00e1ly","family":"Ruppert","sequence":"additional","affiliation":[{"name":"Heart and Vascular Center, Department of Cardiology, Semmelweis University, V\u00e1rosmajor str. 68, H-1122 Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attila","family":"Ol\u00e1h","sequence":"additional","affiliation":[{"name":"Heart and Vascular Center, Department of Cardiology, Semmelweis University, V\u00e1rosmajor str. 68, H-1122 Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K\u00e1lm\u00e1n","family":"Benke","sequence":"additional","affiliation":[{"name":"Heart and Vascular Center, Department of Cardiology, Semmelweis University, V\u00e1rosmajor str. 68, H-1122 Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e1lint","family":"Barta","sequence":"additional","affiliation":[{"name":"Heart and Vascular Center, Department of Cardiology, Semmelweis University, V\u00e1rosmajor str. 68, H-1122 Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eszter","family":"Zs\u00e1ry","sequence":"additional","affiliation":[{"name":"Heart and Vascular Center, Department of Cardiology, Semmelweis University, V\u00e1rosmajor str. 68, H-1122 Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9la","family":"Merkely","sequence":"additional","affiliation":[{"name":"Heart and Vascular Center, Department of Cardiology, Semmelweis University, V\u00e1rosmajor str. 68, H-1122 Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tam\u00e1s","family":"Radovits","sequence":"additional","affiliation":[{"name":"Heart and Vascular Center, Department of Cardiology, Semmelweis University, V\u00e1rosmajor str. 68, H-1122 Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1161\/CIR.0000000000000950","article-title":"Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association","volume":"143","author":"Virani","year":"2021","journal-title":"Circulation"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1172\/JCI116972","article-title":"The human kidney low affinity Na+\/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose","volume":"93","author":"Kanai","year":"1994","journal-title":"J. Clin. Invest."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1681\/ASN.2010030246","article-title":"SGLT2 mediates glucose reabsorption in the early proximal tubule","volume":"22","author":"Vallon","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"F188","DOI":"10.1152\/ajprenal.00518.2013","article-title":"Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia","volume":"306","author":"Rieg","year":"2014","journal-title":"Am. J. Physiol.-Ren. Physiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6791","DOI":"10.1038\/s41598-018-25054-y","article-title":"High Basolateral Glucose Increases Sodium-Glucose Cotransporter 2 and Reduces Sirtuin-1 in Renal Tubules through Glucose Transporter-2 Detection","volume":"8","author":"Umino","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/clpt.2008.251","article-title":"Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects","volume":"85","author":"Komoroski","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Cefalo, C.M.A., Cinti, F., Moffa, S., Impronta, F., Sorice, G.P., Mezza, T., Pontecorvi, A., and Giaccari, A. (2019). Sotagliflozin, the first dual SGLT inhibitor: Current outlook and perspectives. Cardiovasc. Diabetol., 18.","DOI":"10.1186\/s12933-019-0828-y"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2337\/dc14-0890","article-title":"Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy","volume":"38","author":"Rosenstock","year":"2015","journal-title":"Diabetes Care"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1007\/s00125-015-3710-9","article-title":"Mechanisms through which a small protein and lipid preload improves glucose tolerance","volume":"58","author":"Trico","year":"2015","journal-title":"Diabetologia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 Inhibitors with Cardiovascular and Kidney Outcomes in Patients with Type 2 Diabetes: A Meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Anker, S.D., Butler, J., Filippatos, G., Ferreira, J.P., Bocchi, E., Bohm, M., Brunner-La Rocca, H.P., Choi, D.J., Chopra, V., and Chuquiure-Valenzuela, E. (2021). Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa2107038"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/cvr\/cvaa064","article-title":"Critical examination of mechanisms underlying the reduction in heart failure events with SGLT2 inhibitors: Identification of a molecular link between their actions to stimulate erythrocytosis and to alleviate cellular stress","volume":"117","author":"Packer","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: Mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"23","DOI":"10.15420\/ecr.2018.34.2","article-title":"Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments","volume":"14","author":"Tamargo","year":"2019","journal-title":"Eur. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review","volume":"75","author":"Zelniker","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s10741-020-10038-w","article-title":"SGLT2-inhibitors; more than just glycosuria and diuresis","volume":"26","author":"Fathi","year":"2021","journal-title":"Heart Fail. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"CV Protection in the EMPA-REG OUTCOME Trial: A \u201cThrifty Substrate\u201d Hypothesis","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/cvr\/cvx149","article-title":"Cardiac effects of SGLT2 inhibitors: The sodium hypothesis","volume":"114","author":"Bertero","year":"2018","journal-title":"Cardiovasc. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","article-title":"Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function","volume":"83","author":"Vallon","year":"2021","journal-title":"Annu. Rev. Physiol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Garcia-Ropero, A., Vargas-Delgado, A.P., Santos-Gallego, C.G., and Badimon, J.J. (2019). Inhibition of Sodium Glucose Cotransporters Improves Cardiac Performance. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20133289"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00125-020-05359-2","article-title":"Sodium-glucose cotransporter 2 inhibitors reduce myocardial infarct size in preclinical animal models of myocardial ischaemia-reperfusion injury: A meta-analysis","volume":"64","author":"Sayour","year":"2021","journal-title":"Diabetologia"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Bjornstad, P., Greasley, P.J., Wheeler, D.C., Chertow, G.M., Langkilde, A.M., Heerspink, H.J.L., and van Raalte, D.H. (2021). The potential roles of osmotic and non-osmotic sodium handling in mediating effects of SGLT2 inhibitors on heart failure. J. Card. Fail.","DOI":"10.1016\/j.cardfail.2021.07.003"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: A meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.119.042929","article-title":"Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients with Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial","volume":"140","author":"Nassif","year":"2019","journal-title":"Circulation"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.jacc.2021.01.033","article-title":"Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial","volume":"77","author":"Packer","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Kondo, H., Akoumianakis, I., Badi, I., Akawi, N., Kotanidis, C.P., Polkinghorne, M., Stadiotti, I., Sommariva, E., Antonopoulos, A.S., and Carena, M.C. (2021). Effects of canagliflozin on human myocardial redox signalling: Clinical implications. Eur. Heart J.","DOI":"10.1093\/eurheartj\/ehab420"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/jcb.10631","article-title":"Human cardiomyocytes express high level of Na+\/glucose cotransporter 1 (SGLT1)","volume":"90","author":"Zhou","year":"2003","journal-title":"J. Cell Biochem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s13300-010-0006-4","article-title":"Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members","volume":"1","author":"Chen","year":"2010","journal-title":"Diabetes Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"41166","DOI":"10.1038\/srep41166","article-title":"Sodium-myoinositol cotransporter-1, SMIT1, mediates the production of reactive oxygen species induced by hyperglycemia in the heart","volume":"7","author":"Balteau","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ijcard.2017.05.032","article-title":"Sodium-dependent glucose transporters (SGLT) in human ischemic heart: A new potential pharmacological target","volume":"243","author":"Cantini","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/eurjhf\/hfp191","article-title":"Functional effects of glucose transporters in human ventricular myocardium","volume":"12","author":"Gasser","year":"2010","journal-title":"Eur. J. Heart Fail."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Sayour, A.A., Olah, A., Ruppert, M., Barta, B.A., Horvath, E.M., Benke, K., Polos, M., Hartyanszky, I., Merkely, B., and Radovits, T. (2020). Characterization of left ventricular myocardial sodium-glucose cotransporter 1 expression in patients with end-stage heart failure. Cardiovasc. Diabetol., 19.","DOI":"10.1186\/s12933-020-01141-1"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","article-title":"Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)\/H(+) exchanger in rats and rabbits","volume":"60","author":"Baartscheer","year":"2017","journal-title":"Diabetologia"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","article-title":"Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: Inhibition of Na(+)\/H(+) exchanger, lowering of cytosolic Na(+) and vasodilation","volume":"61","author":"Uthman","year":"2018","journal-title":"Diabetologia"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Zuurbier, C.J., Baartscheer, A., Schumacher, C.A., Fiolet, J.W.T., and Coronel, R. (2021). SGLT2 inhibitor empagliflozin inhibits the cardiac Na+\/H+ exchanger 1: Persistent inhibition under various experimental conditions. Cardiovasc. Res.","DOI":"10.1093\/cvr\/cvab129"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1093\/cvr\/cvz004","article-title":"Delayed ischaemic contracture onset by empagliflozin associates with NHE1 inhibition and is dependent on insulin in isolated mouse hearts","volume":"115","author":"Uthman","year":"2019","journal-title":"Cardiovasc. Res."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Chung, Y.J., Park, K.C., Tokar, S., Eykyn, T.R., Fuller, W., Pavlovic, D., Swietach, P., and Shattock, M.J. (2020). Off-target effects of SGLT2 blockers: Empagliflozin does not inhibit Na+\/H+ exchanger-1 or lower [Na+]i in the heart. Cardiovasc. Res.","DOI":"10.1093\/cvr\/cvaa323"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1161\/CIRCULATIONAHA.121.053350","article-title":"Cardiac Late Sodium Channel Current Is a Molecular Target for the Sodium\/Glucose Cotransporter 2 Inhibitor Empagliflozin","volume":"143","author":"Philippaert","year":"2021","journal-title":"Circulation"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e018298","DOI":"10.1161\/JAHA.120.018298","article-title":"Direct Cardiac Actions of the Sodium Glucose Co-Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure-Overload Heart Failure","volume":"10","author":"Li","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","article-title":"Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: Characterisation and comparison with other SGLT-2 inhibitors","volume":"14","author":"Grempler","year":"2012","journal-title":"Diabetes Obes. Metab."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jacc.2019.11.036","article-title":"Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review","volume":"75","author":"Zelniker","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/cvr\/cvp190","article-title":"SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states","volume":"84","author":"Banerjee","year":"2009","journal-title":"Cardiovasc. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.jacc.2018.07.061","article-title":"Genetic Variants in SGLT1, Glucose Tolerance, and Cardiometabolic Risk","volume":"72","author":"Seidelmann","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Katzmann, J.L., Mason, A.M., Marz, W., Kleber, M.E., Niessner, A., Bluher, M., Speer, T., and Laufs, U. (2021). Genetic variation in sodium-glucose cotransporter 2 and heart failure. Clin. Pharmacol. Ther.","DOI":"10.1002\/cpt.2153"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e002183","DOI":"10.1161\/JAHA.115.002183","article-title":"Intracellular Na+ Concentration ([Na+]i) Is Elevated in Diabetic Hearts Due to Enhanced Na+-Glucose Cotransport","volume":"4","author":"Lambert","year":"2015","journal-title":"J. Am. Heart Assoc."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1093\/cvr\/cvz037","article-title":"Cardiac sodium-dependent glucose cotransporter 1 is a novel mediator of ischaemia\/reperfusion injury","volume":"115","author":"Li","year":"2019","journal-title":"Cardiovasc. Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.bbrc.2016.02.016","article-title":"Inhibition of SGLT1 abrogates preconditioning-induced cardioprotection against ischemia-reperfusion injury","volume":"472","author":"Kanwal","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jphs.2019.11.001","article-title":"Pretreatment with KGA-2727, a selective SGLT1 inhibitor, is protective against myocardial infarction-induced ventricular remodeling and heart failure in mice","volume":"142","author":"Sawa","year":"2020","journal-title":"J. Pharmacol. Sci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.diabet.2017.09.008","article-title":"Temporal characterization of cardiac expression of glucose transporters SGLT and GLUT in an experimental model of myocardial infarction","volume":"45","author":"Lax","year":"2019","journal-title":"Diabetes Metab."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1536\/ihj.17-565","article-title":"Chronic Pressure Overload Induces Cardiac Hypertrophy and Fibrosis via Increases in SGLT1 and IL-18 Gene Expression in Mice","volume":"59","author":"Matsushita","year":"2018","journal-title":"Int. Heart J."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Sayour, A.A., Ruppert, M., Ol\u00e1h, A., Benke, K., Barta, B.A., Zs\u00e1ry, E., Ke, H., Horv\u00e1th, E.M., Merkely, B., and Radovits, T. (2021). Left Ventricular SGLT1 Protein Expression Correlates with the Extent of Myocardial Nitro-Oxidative Stress in Rats with Pressure and Volume Overload-Induced Heart Failure. Antioxidants, 10.","DOI":"10.3390\/antiox10081190"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10557-017-6725-2","article-title":"SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3\/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor","volume":"31","author":"Ye","year":"2017","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"119116","DOI":"10.1016\/j.lfs.2021.119116","article-title":"Inhibition of SGLT1 protects against glycemic variability-induced cardiac damage and pyroptosis of cardiomyocytes in diabetic mice","volume":"271","author":"Sun","year":"2021","journal-title":"Life Sci."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"108968","DOI":"10.1016\/j.abb.2021.108968","article-title":"Glucose fluctuation accelerates cardiac injury of diabetic mice via sodium-dependent glucose cotransporter 1 (SGLT1)","volume":"709","author":"Wu","year":"2021","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"700366","DOI":"10.3389\/fphar.2021.700366","article-title":"SGLT1 Knockdown Attenuates Cardiac Fibroblast Activation in Diabetic Cardiac Fibrosis","volume":"12","author":"Lin","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Yoshii, A., Nagoshi, T., Kashiwagi, Y., Kimura, H., Tanaka, Y., Oi, Y., Ito, K., Yoshino, T., Tanaka, T.D., and Yoshimura, M. (2019). Cardiac ischemia-reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity. Cardiovasc. Diabetol., 18.","DOI":"10.1186\/s12933-019-0889-y"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Connelly, K.A., Zhang, Y., Desjardins, J.F., Thai, K., and Gilbert, R.E. (2018). Dual inhibition of sodium-glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction. Cardiovasc. Diabetol., 17.","DOI":"10.1186\/s12933-018-0741-9"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Kashiwagi, Y., Nagoshi, T., Yoshino, T., Tanaka, T.D., Ito, K., Harada, T., Takahashi, H., Ikegami, M., Anzawa, R., and Yoshimura, M. (2015). Expression of SGLT1 in human hearts and impairment of cardiac glucose uptake by phlorizin during ischemia-reperfusion injury in mice. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0130605"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.yjmcc.2010.06.003","article-title":"SGLT1, a novel cardiac glucose transporter, mediates increased glucose uptake in PRKAG2 cardiomyopathy","volume":"49","author":"Banerjee","year":"2010","journal-title":"J. Mol. Cell Cardiol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e000899","DOI":"10.1161\/JAHA.114.000899","article-title":"Transgenic knockdown of cardiac sodium\/glucose cotransporter 1 (SGLT1) attenuates PRKAG2 cardiomyopathy, whereas transgenic overexpression of cardiac SGLT1 causes pathologic hypertrophy and dysfunction in mice","volume":"3","author":"Ramratnam","year":"2014","journal-title":"J. Am. Heart Assoc."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"F634","DOI":"10.1152\/ajprenal.00217.2003","article-title":"Signaling cascade of ANG II-induced inhibition of alpha-MG uptake in renal proximal tubule cells","volume":"286","author":"Han","year":"2004","journal-title":"Am. J. Physiol.-Ren. Physiol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/jcp.10438","article-title":"Epidermal growth factor inhibits 14C-alpha-methyl-D-glucopyranoside uptake in renal proximal tubule cells: Involvement of PLC\/PKC, p44\/42 MAPK, and cPLA2","volume":"199","author":"Taub","year":"2004","journal-title":"J. Cell Physiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.bbrc.2003.12.090","article-title":"Na(+)-D-glucose cotransporter in muscle capillaries increases glucose permeability","volume":"314","author":"Elfeber","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_73","first-page":"6887","article-title":"Role of SGLT1 in high glucose level-induced MMP-2 expression in human cardiac fibroblasts","volume":"17","author":"Meng","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1007\/s00424-014-1619-7","article-title":"Localizations of Na(+)-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart","volume":"467","author":"Vrhovac","year":"2015","journal-title":"Pflugers Arch.-Eur. J. Physiol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.1113\/JP271904","article-title":"Revisiting the physiological roles of SGLTs and GLUTs using positron emission tomography in mice","volume":"594","author":"Hirayama","year":"2016","journal-title":"J. Physiol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"H838","DOI":"10.1152\/ajpheart.00736.2019","article-title":"New insight in understanding the contribution of SGLT1 in cardiac glucose uptake: Evidence for a truncated form in mice and humans","volume":"320","author":"Ferte","year":"2021","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/cvr\/cvr230","article-title":"NADPH oxidase activation by hyperglycaemia in cardiomyocytes is independent of glucose metabolism but requires SGLT1","volume":"92","author":"Balteau","year":"2011","journal-title":"Cardiovasc. Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1161\/01.CIR.0000016701.85760.97","article-title":"Intracellular Na(+) concentration is elevated in heart failure but Na\/K pump function is unchanged","volume":"105","author":"Despa","year":"2002","journal-title":"Circulation"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1161\/01.RES.0000232546.92777.05","article-title":"Elevated cytosolic Na+ decreases mitochondrial Ca2+ uptake during excitation-contraction coupling and impairs energetic adaptation in cardiac myocytes","volume":"99","author":"Maack","year":"2006","journal-title":"Circ. Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12967-019-1881-8","article-title":"Acute canagliflozin treatment protects against in vivo myocardial ischemia-reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation","volume":"17","author":"Sayour","year":"2019","journal-title":"J. Transl. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.brainres.2012.10.020","article-title":"Post-ischemic hyperglycemia exacerbates the development of cerebral ischemic neuronal damage through the cerebral sodium-glucose transporter","volume":"1489","author":"Yamazaki","year":"2012","journal-title":"Brain Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.neuroscience.2015.10.005","article-title":"Activation of cerebral sodium-glucose transporter type 1 function mediated by post-ischemic hyperglycemia exacerbates the development of cerebral ischemia","volume":"310","author":"Yamazaki","year":"2015","journal-title":"Neuroscience"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"F1201","DOI":"10.1152\/ajprenal.00111.2019","article-title":"Gene deletion of the Na(+)-glucose cotransporter SGLT1 ameliorates kidney recovery in a murine model of acute kidney injury induced by ischemia-reperfusion","volume":"316","author":"Nespoux","year":"2019","journal-title":"Am. J. Physiol.-Ren. Physiol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"F1100","DOI":"10.1152\/ajprenal.00607.2019","article-title":"Gene knockout of the Na(+)-glucose cotransporter SGLT2 in a murine model of acute kidney injury induced by ischemia-reperfusion","volume":"318","author":"Nespoux","year":"2020","journal-title":"Am. J. Physiol.-Ren. Physiol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/18\/9852\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:01:20Z","timestamp":1760166080000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/18\/9852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,12]]},"references-count":84,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["ijms22189852"],"URL":"https:\/\/doi.org\/10.3390\/ijms22189852","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,12]]}}}